<HTML>
<HEAD>
<TITLE>Page 46</TITLE>
<STYLE TYPE="text/css">
<!--
.pg{position:absolute;top:0px;left:0px;height:1056px;width:816px;}
BODY{font-size:12px;color:rgb(0,0,0);background-color:rgb(255,255,255);}
.ps0{position:absolute;top:1013px;left:116px;height:7px;width:21px;}
.ps1{position:absolute;top:114px;left:119px;height:11px;width:538px;}
.ps2{position:absolute;top:132px;left:119px;height:11px;width:519px;}
.ps3{position:absolute;top:151px;left:119px;height:11px;width:538px;}
.ps4{position:absolute;top:169px;left:119px;height:11px;width:554px;}
.ps5{position:absolute;top:187px;left:119px;height:11px;width:555px;}
.ps6{position:absolute;top:206px;left:119px;height:11px;width:550px;}
.ps7{position:absolute;top:224px;left:119px;height:11px;width:514px;}
.ps8{position:absolute;top:242px;left:119px;height:11px;width:510px;}
.ps9{position:absolute;top:261px;left:119px;height:11px;width:532px;}
.ps10{position:absolute;top:279px;left:119px;height:11px;width:548px;}
.ps11{position:absolute;top:297px;left:119px;height:11px;width:556px;}
.ps12{position:absolute;top:316px;left:119px;height:11px;width:537px;}
.ps13{position:absolute;top:334px;left:119px;height:11px;width:561px;}
.ps14{position:absolute;top:352px;left:119px;height:11px;width:557px;}
.ps15{position:absolute;top:371px;left:119px;height:11px;width:510px;}
.ps16{position:absolute;top:389px;left:119px;height:11px;width:465px;}
.ps17{position:absolute;top:407px;left:119px;height:11px;width:128px;}
.ps18{position:absolute;top:441px;left:119px;height:13px;width:485px;}
.ps19{position:absolute;top:460px;left:119px;height:13px;width:543px;}
.ps20{position:absolute;top:486px;left:119px;height:10px;width:459px;}
.ps21{position:absolute;top:503px;left:119px;height:11px;width:535px;}
.ps22{position:absolute;top:521px;left:119px;height:11px;width:484px;}
.ps23{position:absolute;top:540px;left:119px;height:11px;width:566px;}
.ps24{position:absolute;top:558px;left:119px;height:11px;width:548px;}
.ps25{position:absolute;top:576px;left:119px;height:11px;width:514px;}
.ps26{position:absolute;top:595px;left:119px;height:11px;width:567px;}
.ps27{position:absolute;top:613px;left:119px;height:11px;width:533px;}
.ps28{position:absolute;top:631px;left:119px;height:11px;width:516px;}
.ps29{position:absolute;top:650px;left:119px;height:11px;width:520px;}
.ps30{position:absolute;top:668px;left:119px;height:11px;width:493px;}
.ps31{position:absolute;top:686px;left:119px;height:11px;width:538px;}
.ps32{position:absolute;top:705px;left:119px;height:11px;width:556px;}
.ps33{position:absolute;top:723px;left:119px;height:11px;width:559px;}
.ps34{position:absolute;top:741px;left:119px;height:11px;width:568px;}
.ps35{position:absolute;top:760px;left:119px;height:11px;width:547px;}
.ps36{position:absolute;top:778px;left:119px;height:11px;width:542px;}
.ps37{position:absolute;top:796px;left:119px;height:11px;width:426px;}
.ps38{position:absolute;top:825px;left:119px;height:10px;width:461px;}
.ps39{position:absolute;top:843px;left:119px;height:11px;width:559px;}
.ps40{position:absolute;top:861px;left:119px;height:11px;width:537px;}
.ps41{position:absolute;top:879px;left:119px;height:11px;width:547px;}
.ps42{position:absolute;top:898px;left:119px;height:11px;width:532px;}
.ps43{position:absolute;top:916px;left:119px;height:11px;width:530px;}
.ps44{position:absolute;top:934px;left:119px;height:11px;width:554px;}
.ps45{position:absolute;top:114px;left:463px;height:11px;width:554px;}
.ps46{position:absolute;top:132px;left:463px;height:11px;width:532px;}
.ps47{position:absolute;top:151px;left:463px;height:11px;width:536px;}
.ps48{position:absolute;top:169px;left:463px;height:11px;width:543px;}
.ps49{position:absolute;top:187px;left:463px;height:11px;width:512px;}
.ps50{position:absolute;top:214px;left:463px;height:11px;width:519px;}
.ps51{position:absolute;top:232px;left:463px;height:11px;width:549px;}
.ps52{position:absolute;top:250px;left:463px;height:11px;width:501px;}
.ps53{position:absolute;top:269px;left:463px;height:11px;width:395px;}
.ps54{position:absolute;top:287px;left:463px;height:11px;width:562px;}
.ps55{position:absolute;top:305px;left:463px;height:11px;width:563px;}
.ps56{position:absolute;top:324px;left:463px;height:11px;width:543px;}
.ps57{position:absolute;top:342px;left:463px;height:11px;width:551px;}
.ps58{position:absolute;top:360px;left:463px;height:11px;width:536px;}
.ps59{position:absolute;top:379px;left:463px;height:11px;width:569px;}
.ps60{position:absolute;top:397px;left:463px;height:11px;width:541px;}
.ps61{position:absolute;top:415px;left:463px;height:11px;width:501px;}
.ps62{position:absolute;top:442px;left:463px;height:11px;width:551px;}
.ps63{position:absolute;top:460px;left:463px;height:11px;width:471px;}
.ps64{position:absolute;top:478px;left:463px;height:11px;width:529px;}
.ps65{position:absolute;top:497px;left:463px;height:11px;width:568px;}
.ps66{position:absolute;top:515px;left:463px;height:11px;width:560px;}
.ps67{position:absolute;top:533px;left:463px;height:11px;width:559px;}
.ps68{position:absolute;top:552px;left:463px;height:11px;width:568px;}
.ps69{position:absolute;top:570px;left:463px;height:11px;width:404px;}
.ps70{position:absolute;top:596px;left:463px;height:11px;width:505px;}
.ps71{position:absolute;top:615px;left:463px;height:11px;width:551px;}
.ps72{position:absolute;top:633px;left:463px;height:11px;width:559px;}
.ps73{position:absolute;top:651px;left:463px;height:11px;width:539px;}
.ps74{position:absolute;top:670px;left:463px;height:11px;width:517px;}
.ps75{position:absolute;top:688px;left:463px;height:11px;width:553px;}
.ps76{position:absolute;top:706px;left:463px;height:11px;width:552px;}
.ps77{position:absolute;top:725px;left:463px;height:11px;width:544px;}
.ps78{position:absolute;top:743px;left:463px;height:11px;width:555px;}
.ps79{position:absolute;top:761px;left:463px;height:11px;width:353px;}
.ps80{position:absolute;top:790px;left:463px;height:10px;width:514px;}
.ps81{position:absolute;top:808px;left:463px;height:11px;width:567px;}
.ps82{position:absolute;top:826px;left:463px;height:11px;width:536px;}
.ps83{position:absolute;top:844px;left:463px;height:11px;width:504px;}
.ps84{position:absolute;top:863px;left:463px;height:11px;width:568px;}
.ps85{position:absolute;top:881px;left:463px;height:11px;width:548px;}
.ps86{position:absolute;top:899px;left:463px;height:11px;width:499px;}
.ps87{position:absolute;top:918px;left:463px;height:11px;width:517px;}
.ps88{position:absolute;top:936px;left:463px;height:11px;width:531px;}
.ft0{font-size:8px;font-family:sans-serif;white-space:pre;}
.ft1{font-family:sans-serif;white-space:pre;}
.ft2{font-weight:bold;font-size:11px;font-family:sans-serif;white-space:pre;}
.ft3{font-weight:bold;font-family:sans-serif;white-space:pre;}
.em0{font-weight:bold;font-family:"Times New Roman",Times,serif;}
.em1{}
.em2{}
.em3{}
-->
</STYLE>
<script language="JavaScript">
<!--
function MM_reloadPage(init) {  //reloads the window if Nav4 resized
  if (init==true) with (navigator) {if ((appName=="Netscape")&&(parseInt(appVersion)==4)) {
    document.MM_pgW=innerWidth; document.MM_pgH=innerHeight; onresize=MM_reloadPage; }}
  else if (innerWidth!=document.MM_pgW || innerHeight!=document.MM_pgH) location.reload();
}
MM_reloadPage(true);
// -->
</script>
</HEAD>

<BODY>
<p class="ft3">&nbsp;</p>
<div id="Layer2" style="position:absolute; width:78px; height:21px; left: 573px; top: 931px"><a href="page47HFandACE.html" target="_self">To 
  next page</a></div>
<SPAN CLASS="ps0" style="width: 21px; left: 30px; top: 940"><SPAN CLASS="ft0">46</SPAN></SPAN> 
<SPAN CLASS="ps1" style="left: 25px; top: 50; width: 325"><SPAN CLASS="ft1">The 
goal of treatment in older patients should</SPAN></SPAN> <SPAN CLASS="ps2" style="width: 325; left: 25px; top: 69"><SPAN CLASS="ft1">be 
the same as in younger patients (to below</SPAN></SPAN> <SPAN CLASS="ps3" style="top: 88; left: 25px; width: 325"><SPAN CLASS="ft1">140/90 
mm Hg if at all possible), although an</SPAN></SPAN> <SPAN CLASS="ps4" style="width: 325; left: 25px; top: 107"><SPAN CLASS="ft1">interim 
goal of SBP below 160 mm Hg may be</SPAN></SPAN> <SPAN CLASS="ps5" style="width: 325; left: 25px; top: 126"><SPAN CLASS="ft1">necessary 
in those patients with marked systolic</SPAN></SPAN> <SPAN CLASS="ps6" style="width: 325; left: 25px; top: 143"><SPAN CLASS="ft1">hypertension.<SPAN CLASS="em2"><SUP>26<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;Any 
reduction in blood pres-</SPAN></SPAN> <SPAN CLASS="ps7" style="width: 325; left: 25px; top: 164"><SPAN CLASS="ft1">sure 
appears to confer benefit&#151;the closer to</SPAN></SPAN> <SPAN CLASS="ps8" style="width: 325; left: 25px; top: 183"><SPAN CLASS="ft1">normal, 
the greater the benefit. &#160;Drugs that</SPAN></SPAN> <SPAN CLASS="ps9" style="width: 325; left: 25px; top: 202"><SPAN CLASS="ft1">exaggerate 
postural changes in blood pressure</SPAN></SPAN> <SPAN CLASS="ps10" style="width: 325; left: 25px; top: 221"><SPAN CLASS="ft1">(peripheral 
adrenergic blockers, alpha-blockers,</SPAN></SPAN> <SPAN CLASS="ps11" style="width: 325; left: 25px; top: 240"><SPAN CLASS="ft1">and 
high-dose diuretics) or drugs that can cause</SPAN></SPAN> <SPAN CLASS="ps12" style="width: 325; left: 25px; top: 259"><SPAN CLASS="ft1">cognitive 
dysfunction (central alpha<SPAN CLASS="em2"><SUB>2<SPAN CLASS="em3"><SUP>-agonists)</SUP></SPAN></SUB></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps13" style="width: 325; left: 25px; top: 278px"><SPAN CLASS="ft1">should 
be used with caution. &#160;Additional recom-</SPAN></SPAN> <SPAN CLASS="ps14" style="width: 325; left: 25px; top: 297px"><SPAN CLASS="ft1">mendations 
about hypertension in older persons</SPAN></SPAN> <SPAN CLASS="ps15" style="width: 325; left: 25px; top: 316; height: 11px"><SPAN CLASS="ft1">can 
be found in the report by the NHBPEP</SPAN></SPAN> <SPAN CLASS="ps16" style="height: 11px; left: 25px; top: 335; width: 325"><SPAN CLASS="ft1">Working 
Group on Hypertension in the</SPAN></SPAN> <SPAN CLASS="ps17" style="top: 352; left: 25px; width: 128px"><SPAN CLASS="ft1">Elderly.<SPAN CLASS="em2"><SUP>26<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps18" style="left: 25px; top: 383; width: 325"><SPAN CLASS="ft2">P<SPAN CLASS="em1">ATIENTS</SPAN>&#160;W<SPAN CLASS="em1">ITH</SPAN>&#160;H<SPAN CLASS="em1">YPERTENSION</SPAN><SPAN CLASS="em1"> 
</SPAN>&#160;<SPAN CLASS="em1">AND</SPAN></SPAN></SPAN> <SPAN CLASS="ps19" style="width: 325; left: 25px; top: 402"><SPAN CLASS="ft2">C<SPAN CLASS="em1">OEXISTING</SPAN>&#160;C<SPAN CLASS="em1">ARDIOVASCULAR</SPAN>&#160;D<SPAN CLASS="em1">ISEASES</SPAN></SPAN></SPAN> 
<SPAN CLASS="ps20" style="width: 325; left: 25px; top: 425"><SPAN CLASS="ft3">Patients 
With Cerebrovascular Disease</SPAN></SPAN> <SPAN CLASS="ps21" style="width: 325; left: 25px; top: 445"><SPAN CLASS="ft1">Clinically 
evident cerebrovascular disease is an</SPAN></SPAN> <SPAN CLASS="ps22" style="top: 464; left: 25px; width: 325"><SPAN CLASS="ft1">indication 
for antihypertensive treatment.</SPAN></SPAN> <SPAN CLASS="ps23" style="width: 325; left: 25px; top: 483"><SPAN CLASS="ft1">However, 
immediately after the occurrence of an</SPAN></SPAN> <SPAN CLASS="ps24" style="width: 325; left: 25px; top: 502"><SPAN CLASS="ft1">ischemic 
cerebral infarction, it is appropriate to</SPAN></SPAN> <SPAN CLASS="ps25" style="width: 325; left: 25px; top: 521"><SPAN CLASS="ft1">withhold 
treatment (unless blood pressure is</SPAN></SPAN> <SPAN CLASS="ps26" style="width: 325; left: 25px; top: 540"><SPAN CLASS="ft1">very 
high) until the situation has been stabilized.</SPAN></SPAN> <SPAN CLASS="ps27" style="width: 325; left: 25px; top: 559"><SPAN CLASS="ft1">Even 
when treatment has been withheld tem-</SPAN></SPAN> <SPAN CLASS="ps28" style="width: 325; left: 25px; top: 578"><SPAN CLASS="ft1">porarily, 
the eventual goal is to reduce blood</SPAN></SPAN> <SPAN CLASS="ps29" style="width: 325; left: 25px; top: 597"><SPAN CLASS="ft1">pressure 
gradually while avoiding orthostatic</SPAN></SPAN> <SPAN CLASS="ps30" style="width: 325; left: 25px; top: 616"><SPAN CLASS="ft1">hypotension. 
&#160;Patients with acute ischemic</SPAN></SPAN> <SPAN CLASS="ps31" style="left: 25px; top: 635; width: 325px"><SPAN CLASS="ft1">stroke 
who are treated with fibrinolytic agents</SPAN></SPAN> <SPAN CLASS="ps32" style="width: 325; left: 25px; top: 654"><SPAN CLASS="ft1">require 
careful blood pressure monitoring, espe-</SPAN></SPAN> <SPAN CLASS="ps33" style="width: 325; left: 25px; top: 673"><SPAN CLASS="ft1">cially 
over the first 24 hours after starting treat-</SPAN></SPAN> <SPAN CLASS="ps34" style="width: 325; left: 25px; top: 692"><SPAN CLASS="ft1">ment. 
&#160;SBP of 180 mm Hg or greater or DBP of</SPAN></SPAN> <SPAN CLASS="ps35" style="width: 325; left: 25px; top: 711"><SPAN CLASS="ft1">105 
mm Hg or greater may be controlled with</SPAN></SPAN> <SPAN CLASS="ps36" style="width: 325; left: 25px; top: 730"><SPAN CLASS="ft1">intravenous 
agents with careful monitoring for</SPAN></SPAN> <SPAN CLASS="ps37" style="width: 325px; left: 25px; top: 747"><SPAN CLASS="ft1">worsening 
of neurological status.<SPAN CLASS="em2"><SUP>175<SPAN CLASS="em0">C</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps38" style="top: 775; left: 25px; width: 325"><SPAN CLASS="ft3">Patients 
With Coronary Artery Disease</SPAN></SPAN> <SPAN CLASS="ps39" style="width: 325; left: 25px; top: 794"><SPAN CLASS="ft1">Patients 
with coronary artery disease and hyper-</SPAN></SPAN> <SPAN CLASS="ps40" style="width: 325; left: 25px; top: 813px"><SPAN CLASS="ft1">tension 
are at particularly high risk for cardio-</SPAN></SPAN> <SPAN CLASS="ps41" style="left: 25px; top: 832; width: 325"><SPAN CLASS="ft1">vascular 
morbidity and mortality. &#160;The benefits</SPAN></SPAN> <SPAN CLASS="ps42" style="width: 325; left: 25px; top: 851"><SPAN CLASS="ft1">and 
safety of antihypertensive therapy in such</SPAN></SPAN> <SPAN CLASS="ps43" style="width: 325; left: 25px; top: 868"><SPAN CLASS="ft1">patients 
are well established.<SPAN CLASS="em2"><SUP>176<SPAN CLASS="em0">Pr,</SPAN>177<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;&#160;Exces-</SPAN></SPAN> 
<SPAN CLASS="ps44" style="width: 325; left: 25px; top: 889"><SPAN CLASS="ft1">sively 
rapid lowering of blood pressure, particu-</SPAN></SPAN> <SPAN CLASS="ps45" style="top: 50; left: 369px; width: 300"><SPAN CLASS="ft1">larly 
when it causes reflex tachycardia and sym-</SPAN></SPAN> <SPAN CLASS="ps46" style="width: 300; left: 369px; top: 69"><SPAN CLASS="ft1">pathetic 
activation, should be avoided. &#160;Blood</SPAN></SPAN> <SPAN CLASS="ps47" style="left: 369px; top: 88; width: 300"><SPAN CLASS="ft1">pressure 
should be lowered to the usual target</SPAN></SPAN> <SPAN CLASS="ps48" style="width: 300; left: 369px; top: 107"><SPAN CLASS="ft1">range 
(below 140/90 mm Hg), and even lower</SPAN></SPAN> <SPAN CLASS="ps49" style="left: 369px; top: 126; width: 300"><SPAN CLASS="ft1">blood 
pressure is desirable if angina persists.</SPAN></SPAN> <SPAN CLASS="ps50" style="width: 300; left: 369px; top: 150; height: 11px"><SPAN CLASS="ft1">Beta-blockers 
or calcium antagonists may be</SPAN></SPAN> <SPAN CLASS="ps51" style="top: 169; left: 369px; width: 300"><SPAN CLASS="ft1">specifically 
useful in patients with hypertension</SPAN></SPAN> <SPAN CLASS="ps52" style="left: 369px; top: 188; width: 300"><SPAN CLASS="ft1">and 
angina pectoris; however, short-acting </SPAN></SPAN> <SPAN CLASS="ps53" style="width: 300; left: 369px; top: 207"><SPAN CLASS="ft1">calcium 
antagonists should not be</SPAN></SPAN> <SPAN CLASS="ps54" style="width: 300; left: 369px; top: 224"><SPAN CLASS="ft1">used.<SPAN CLASS="em2"><SUP>125<SPAN CLASS="em0">M,</SPAN>178<SPAN CLASS="em0">Re</SPAN>179<SPAN CLASS="em0">Re</SPAN></SUP></SPAN>&#160;&#160;After 
myocardial infarction,</SPAN></SPAN> <SPAN CLASS="ps55" style="width: 300; left: 369px; top: 245"><SPAN CLASS="ft1">beta-blockers 
without intrinsic sympathomimet-</SPAN></SPAN> <SPAN CLASS="ps56" style="width: 300; left: 369px; top: 264"><SPAN CLASS="ft1">ic 
activity should be given because they reduce</SPAN></SPAN> <SPAN CLASS="ps57" style="width: 300; left: 369px; top: 283px"><SPAN CLASS="ft1">the 
risk for subsequent myocardial infarction or</SPAN></SPAN> <SPAN CLASS="ps58" style="width: 300; left: 369px; top: 302"><SPAN CLASS="ft1">sudden 
cardiac death. &#160;ACE inhibitors are also</SPAN></SPAN> <SPAN CLASS="ps59" style="width: 300; left: 369px; top: 321"><SPAN CLASS="ft1">useful 
after myocardial infarction, especially with</SPAN></SPAN> <SPAN CLASS="ps60" style="width: 300; left: 369px; top: 340"><SPAN CLASS="ft1">left 
ventricular systolic dysfunction, to prevent</SPAN></SPAN> <SPAN CLASS="ps61" style="width: 300; left: 369px; top: 357"><SPAN CLASS="ft1">subsequent 
heart failure and mortality.<SPAN CLASS="em2"><SUP>176<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps62" style="width: 300; left: 369px; top: 383"><SPAN CLASS="ft1">If 
beta-blockers are ineffective or contraindicat-</SPAN></SPAN> <SPAN CLASS="ps63" style="width: 300; left: 369px; top: 402"><SPAN CLASS="ft1">ed, 
verapamil hydrochloride or diltiazem</SPAN></SPAN> <SPAN CLASS="ps64" style="width: 300; left: 369px; top: 421"><SPAN CLASS="ft1">hydrochloride 
may be used because they have</SPAN></SPAN> <SPAN CLASS="ps65" style="width: 300; left: 369px; top: 440"><SPAN CLASS="ft1">been 
shown to reduce cardiac events and mortal-</SPAN></SPAN> <SPAN CLASS="ps66" style="width: 300; left: 369px; top: 459"><SPAN CLASS="ft1">ity 
modestly in two circumstances: (1) following</SPAN></SPAN> <SPAN CLASS="ps67" style="width: 300; left: 369px; top: 478"><SPAN CLASS="ft1">non-Q-wave 
myocardial infarction, and (2) after</SPAN></SPAN> <SPAN CLASS="ps68" style="width: 300; left: 369px; top: 497"><SPAN CLASS="ft1">myocardial 
infarction with preserved left ventric-</SPAN></SPAN> <SPAN CLASS="ps69" style="width: 300; left: 369px; top: 514"><SPAN CLASS="ft1">ular 
function (LVH).<SPAN CLASS="em2"><SUP>119<SPAN CLASS="em0">Pr</SPAN>,180<SPAN CLASS="em0">Pr</SPAN>,181<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps70" style="left: 369px; top: 540; width: 300"><SPAN CLASS="ft1">Some 
patients with hypertension, especially</SPAN></SPAN> <SPAN CLASS="ps71" style="left: 369px; top: 559; width: 300"><SPAN CLASS="ft1">when 
accompanied by severe LVH, may experi-</SPAN></SPAN> <SPAN CLASS="ps72" style="width: 300; left: 369px; top: 578"><SPAN CLASS="ft1">ence 
angina without evidence of coronary ather-</SPAN></SPAN> <SPAN CLASS="ps73" style="width: 300; left: 369px; top: 597"><SPAN CLASS="ft1">osclerosis. 
&#160;This is thought to reflect an imbal-</SPAN></SPAN> <SPAN CLASS="ps74" style="width: 300; left: 369px; top: 616"><SPAN CLASS="ft1">ance 
between myocardial oxygen supply and</SPAN></SPAN> <SPAN CLASS="ps75" style="width: 300; left: 369px; top: 635"><SPAN CLASS="ft1">demand, 
due in part to changes in the coronary</SPAN></SPAN> <SPAN CLASS="ps76" style="width: 300; left: 369px; top: 654"><SPAN CLASS="ft1">microcirculation. 
&#160;Treatment should be directed</SPAN></SPAN> <SPAN CLASS="ps77" style="width: 300; left: 369px; top: 673"><SPAN CLASS="ft1">at 
blood pressure control, reversal of LVH, and</SPAN></SPAN> <SPAN CLASS="ps78" style="width: 300; left: 369px; top: 692"><SPAN CLASS="ft1">avoidance 
of tachycardia, which may exacerbate</SPAN></SPAN> <SPAN CLASS="ps79" style="width: 300; left: 369px; top: 711"><SPAN CLASS="ft1">the 
supply-demand mismatch.</SPAN></SPAN> <SPAN CLASS="ps80" style="width: 300; left: 369px; top: 737"><SPAN CLASS="ft3">Patients 
With Left Ventricular Hypertrophy</SPAN></SPAN> <SPAN CLASS="ps81" style="width: 300; left: 369px; top: 756"><SPAN CLASS="ft1">Development 
of LVH permits cardiac adaptation</SPAN></SPAN> <SPAN CLASS="ps82" style="width: 300; left: 369px; top: 775"><SPAN CLASS="ft1">to 
the increased afterload imposed by elevated</SPAN></SPAN> <SPAN CLASS="ps83" style="width: 300; left: 369px; top: 794"><SPAN CLASS="ft1">arterial 
pressure. &#160;However, LVH is a major</SPAN></SPAN> <SPAN CLASS="ps84" style="width: 300; left: 368px; top: 813px"><SPAN CLASS="ft1">independent 
risk factor for sudden cardiac death,</SPAN></SPAN> <SPAN CLASS="ps85" style="width: 300; left: 369px; top: 832"><SPAN CLASS="ft1">myocardial 
infarction, stroke, and other cardio-</SPAN></SPAN> <SPAN CLASS="ps86" style="width: 300; left: 369px; top: 851"><SPAN CLASS="ft1">vascular 
morbid and mortal events.<SPAN CLASS="em2"><SUP>182<SPAN CLASS="em0">F,</SPAN>183<SPAN CLASS="em0">F</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps87" style="width: 300; left: 369px; top: 870"><SPAN CLASS="ft1">Evidence 
shows that antihypertensive agents</SPAN></SPAN> <SPAN CLASS="ps88" style="width: 300; left: 369px; top: 889"><SPAN CLASS="ft1">(except 
direct vasodilators such as hydralazine</SPAN></SPAN> 
</BODY>

</HTML>
